About SELECT SELECT (Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity) was a randomised, double-blind, parallel-group, placebo-controlled trial designed to evaluate the efficacy of semaglutide 2.4 mg versus placebo as an adjunct to standard of care for reducing the risk of MACE in people with established CVD with overweight or obesity with no prior history of diabetes
however higher hepcidin levels are registered in this population, making low serum iron not only dilutional or nutritional, but linking it to chronic systemic low grade inflammation (Tussing-Humphreys et al., 2010)
As of right now, we cannot in good conscience put it on the site
However, anyone experiencing persistent or severe symptoms should consult their healthcare provider to rule out other potential causes and ensure proper management
Youve probably heard claims of faster fat burning, better energy, and quicker recovery